Amifampridine Treatment and Clinical Implementation

Dr. Leal introduces amifampridine, an FDA-approved oral potassium channel blocker that increases acetylcholine release at neuromuscular junctions for treating LEMS, including cancer-associated cases. Two phase 3 trials demonstrated amifampridine versus placebo improved muscle function with significant symptomatic benefits. She asks about Dr. Iams' experience incorporating amifampridine into treatment paradigms while managing active SCLC.

Dr. Iams shares his clinical experience treating a patient with SCLC with severe symptomatic LEMS requiring hospitalization. Initial management included platinum doublet chemotherapy alongside LEMS treatment, beginning with intravenous immunoglobulin (IVIg) and transitioning to amifampridine maintenance. The patient demonstrated excellent initial chemotherapy response, with significant strength improvement over approximately 1 year while on amifampridine maintenance. Progress included advancing from wheelchair dependence to requiring only cane support for ambulation, representing clear symptomatic improvement.

However, disease recurrence occurred after 1 year while continuing amifampridine therapy. Treatment with combination chemotherapy plus checkpoint inhibitor immunotherapy at first recurrence caused severe LEMS flare, requiring wheelchair dependence again. Despite this complication, first response scans showed complete response, enabling cancer-directed therapy cessation. Managing severe LEMS flares required additional interventions including prednisone, IVIg, and potentially plasmapheresis as more aggressive treatment layers alongside amifampridine. The patient's condition improved with time off checkpoint inhibitors, regaining strength and achieving complete response after checkpoint inhibitor exposure.

Regarding prescribing amifampridine, Dr. Iams describes a learning curve but emphasizes extensive templated support and company assistance making the process manageable. Following the "see one, do one, teach one" paradigm, co-management experience with neurology provides foundation for independent prescribing. The uptitration regimen follows clear, plug-and-play protocols with straightforward number-based adjustments and standard follow-up management approaches.

Oncologists possess comfort managing expected toxicities including paresthesias and electrolyte abnormalities, which represent routine monitoring items in cancer treatment settings. While initially intimidating for inexperienced prescribers, the standardized uptitration protocol becomes manageable with experience. Dr. Leal agrees that oncologists can handle monitoring responsibilities given frequent patient clinic visits for SCLC treatment, allowing comprehensive symptom monitoring, caregiver education, and side effect management with nursing and pharmacy support for addressing patient questions and recognizing concerning symptoms.